Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal CancerScott Kopetz, Josep Tabernero, Axel Grothey et al.|New England Journal of Medicine|2019Cited by 1.5k
Duration of Adjuvant Chemotherapy for Stage III Colon CancerAxel Grothey, Timothy Iveson|New England Journal of Medicine|2018Cited by 1.1k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Federico Nasroulah, Radka Obermannová et al.|The Lancet Oncology|2015Cited by 954
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)Axel Grothey, Mark Kozloff, Mary M. Sugrue et al.|Journal of Clinical Oncology|2008Cited by 695
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOSTakayuki Yoshino, Jean‐Yves Douillard, Dirk Arnold et al.|Annals of Oncology|2017Cited by 591